BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding BioCardia, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 24 | 26 | +2 |
| Shares | 2.65M | 2.14M | −513.7K (−19.4%) |
| Value | $5.49M | $3.10M | −$2.38M (−43.4%) |
New holders (4)
Institutions that held BioCardia, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 28,312 | $42.0K | 0.00% |
| Cetera Investment Advisers | 12,610 | $18.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 758 | $1.00K | 0.00% |
| Aspire Private Capital, LLC | 300 | $0 | 0.00% |
Sold out (2)
Institutions that held BioCardia, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Roumell Asset Management, LLC | 536,497 | $1.11M |
| BlackRock Inc. | 34,431 | $72.0K |